Aktis Oncology's AKY-1189 Receives FDA Fast Track Designation
Benzinga Newsdesk 8 months ago
BiotechNewsFDAGeneral
U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b
- U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies
- Ongoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urothelial cancer and several other Nectin-4 expressing tumor types